The imperative to share clinical study reports: recommendations from the Tamiflu experience
PublisherPublic Library of Science
MetadataShow full item record
AbstractSummary points: - Systematic reviews of published randomized clinical trials (RCTs) are considered the gold standard source of synthesized evidence for interventions, but their conclusions are vulnerable to distortion when trial sponsors have strong interests that might benefit from suppressing or promoting selected data. - More reliable evidence synthesis would result from systematic reviewing of clinical study reports—standardized documents representing the most complete record of the planning, execution, and results of clinical trials, which are submitted by industry to government drug regulators. - Unfortunately, industry and regulators have historically treated clinical study reports as confidential documents, impeding additional scrutiny by independent researchers. - We propose clinical study reports become available to such scrutiny, and describe one manufacturer's unconvincing reasons for refusing to provide us access to full clinical study reports. We challenge industry to either provide open access to clinical study reports or publically defend their current position of RCT data secrecy.
CitationDoshi, P., Jefferson, T., Del Mar, C. (2012). The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Medicine, 9(4):e1001201. DOI: 10.1371/journal.pmed.1001201
SponsorsGrant support: 10/80/01/Department of Health/United Kingdom ; HTA/10/80/01/Department of Health/United Kingdom ; T32 HS019488/HS/AHRQ HHS/United States ; T32HS019488/HS/AHRQ HHS/United States
access to documents
clinical study reports
Antiviral Agents--adverse effects
Antiviral Agents--therapeutic use
Outcome Assessment (Health Care)
Randomized Controlled Trials as Topic
Review Literature as Topic
Clinical Trials as Topic
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6666
- The Tamiflu saga continues: will our conduct change after the publication of the latest systematic review on benefits and harms of oseltamivir?
- Authors: Bachelet VC
- Issue date: 2014 May 20
- Open clinical trial data for all? A view from regulators.
- Authors: Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G
- Issue date: 2012
- The Tamiflu trials.
- Authors: Loder E, Tovey D, Godlee F
- Issue date: 2014 Apr 9
- Why don't we have all the evidence on oseltamivir?
- Authors: Godlee F, Clarke M
- Issue date: 2009 Dec 8
- Questions remain over safety and effectiveness of oseltamivir.
- Authors: Cohen D
- Issue date: 2012 Jan 17